

Wednesday, 22 February 2006

## OBJ Appoints Director of Business Development

---

OBJ Limited (ASX: OBJ) is pleased to announce the appointment of Mr. Glyn Denison to the Board of Directors.

Mr Denison will oversee the commercial and market development activities of the company.

Mr Denison has 30 years experience in international business development including 16 years in technology intensive industries, during which time he oversaw annual company revenues rise from a small base to over \$450m per annum.

Mr Denison has worked in Europe, China, South East Asia and Australia and has extensive networks and contacts across the European medical sector.

Mr Denison joins the Board as a non-executive Director however will provide the company with marketing and business development assistance via International Business Development Consultants Pty Ltd. In this role, Mr Denison will work closely with major pharmaceutical companies and potential product partners in the evaluation and commercial exploitation of the company's transdermal Drug delivery technologies.

END:

### Background to the Announcement


OBJ Limited is a drug delivery company, specializing in electronic "drug patch" technologies that allow drugs, vaccines, therapeutic agents and cosmetic compounds to be delivered more effectively and more efficiently through-the-skin.

The OBJ Dermaportation system has been shown to manage and control the transdermal delivery of a broad range of drugs and therapeutic agents ranging from small difficult molecules such as Caffeine, through to large macro-globular proteins drugs such as vaccines.

OBJ's technology has been independently proven in both in-vitro and in-vivo studies and can manage a broader range of molecular sizes, structures and valencies than other active or passive drug delivery systems.

OBJ has been successful in managing the through-the-skin delivery of drugs used in the inflammation, pain, cancer and cosmetic fields.

OBJ's technology is low cost, and can be incorporated into reusable drug patches, (as illustrated) disposable single use drug patches and in a range of packaging systems for OTC and retail use.



### Sustainable Benefits

Low cost and controlled through-the-skin delivery of drugs, hormones, vitamins, vaccines, anti-bodies and anti-aging molecules has long been the desire of the pharmaceutical industry. It would provide economic, safety and efficacy benefits to the pharmacology, medical, veterinary and cosmetic industries. Side effects could be reduced by localized delivery and programmed delivery rates. Needle stick injuries and needle disposable problems could be eliminated while the reduction in the level of skill required for application could significantly reduce total cost of many health programmes. These clear commercial benefits may only be achievable if the skin's natural barrier effect can be overcome.

OBJ is the first company to create a broad spectrum through-the-skin delivery system that is kind to the skin, completely reversible, yet can handle drugs range from the small difficult molecules up to the largest and most complex proteins and anti-bodies. OBJ manages an extensive IP portfolio and prosecutes patent applications throughout the world.

### Independence of Results

OBJ contracts its drug and technology testing programs to independent and respected organisations, such as Western Australian Biomedical Research Institute, Western Australian Institute for Medical Research, Curtin University of Technology and Murdoch University. The high level of independence and international accreditation means that the results attributable to OBJ's proprietary technology can be published and presented at major medical and scientific conferences and forums.

### For more information:

Jeffrey Edwards

Phone: +61 8 944 33011 Mobile: 041 791 2211 E-mail: [jedwards@obj.com.au](mailto:jedwards@obj.com.au)